View Item 

Show simple item record

Chronic hepatitis B Potential conflict of interest: Dr. McMahon's spouse owns stock in GlaxoSmithKline. Dr. Lok is a consultant for, received grants, and is on the Scientific Advisory Board of, Bristol-Myers Squibb, GlaxoSmithKline, Idenix, Roche, Gilead, and Innogenetics. She is also on the Scientific Advisory Board of Pharmasset. Dr. Lok received grants from Schering-Plough. Please refer to www.aasld.org for disclosures by Practice Guidelines Committee members.

dc.contributor.authorLok, Anna Suk-Fongen_US
dc.contributor.authorMcMahon, Brian J.en_US
dc.date.accessioned2007-09-20T18:11:23Z
dc.date.available2008-04-03T18:49:31Zen_US
dc.date.issued2007-02en_US
dc.identifier.citationLok, Anna S. F.; McMahon, Brian J. (2007). "Chronic hepatitis B Potential conflict of interest: Dr. McMahon's spouse owns stock in GlaxoSmithKline. Dr. Lok is a consultant for, received grants, and is on the Scientific Advisory Board of, Bristol-Myers Squibb, GlaxoSmithKline, Idenix, Roche, Gilead, and Innogenetics. She is also on the Scientific Advisory Board of Pharmasset. Dr. Lok received grants from Schering-Plough. Please refer to www.aasld.org for disclosures by Practice Guidelines Committee members. ." Hepatology 45(2): 507-539. <http://hdl.handle.net/2027.42/55941>en_US
dc.identifier.issn0270-9139en_US
dc.identifier.issn1527-3350en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/55941
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17256718&dopt=citationen_US
dc.description.abstractNo abstract.en_US
dc.format.extent495368 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.subject.otherLife and Medical Sciencesen_US
dc.subject.otherHepatologyen_US
dc.titleChronic hepatitis B Potential conflict of interest: Dr. McMahon's spouse owns stock in GlaxoSmithKline. Dr. Lok is a consultant for, received grants, and is on the Scientific Advisory Board of, Bristol-Myers Squibb, GlaxoSmithKline, Idenix, Roche, Gilead, and Innogenetics. She is also on the Scientific Advisory Board of Pharmasset. Dr. Lok received grants from Schering-Plough. Please refer to www.aasld.org for disclosures by Practice Guidelines Committee members.en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI ; fax: 734-936-7392 ; Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109-0362en_US
dc.contributor.affiliationotherLiver Disease and Hepatitis Program, Alaska Native Medical Center and Arctic Investigations Program, Centers for Disease Control, Anchorage, AKen_US
dc.identifier.pmid17256718en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/55941/1/21513_ftp.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1002/hep.21513en_US
dc.identifier.sourceHepatologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
21513_ftp.pdf
Size:
483.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.